Twisted laser light can tell mirror-image drug molecules apart

A right-handed screw fits a right-handed nut. A left-handed screw does not. That geometric rule is why mirror-image drug molecules behave like two different compounds in the body, and a team of Indian researchers has used ultrashort, "twisted" laser pulses to read it.

The molecule camphor comes in two mirror forms, labeled R and S. In pharmaceutical chemistry, those twins are not interchangeable: one form of a drug can ease a symptom while its mirror image causes side effects, which is why chiral analysis is a routine bottleneck in pharmaceutical development. The standard tools for that job, polarimetry, chiral chromatography, and photoelectron circular dichroism, work, but they tend to be slow, finicky, or both.

A team led from the Tata Institute of Fundamental Research (TIFR) Hyderabad, with collaborators at IIT Mumbai and IIT Hyderabad, reports a different route in the journal Science Advances: fire structured laser light that carries orbital angular momentum (OAM), which means the beam's wavefront is shaped like a corkscrew, spinning as it travels, and compare how each camphor twin breaks apart under it. The pulses are a few hundred femtoseconds long, fired at the TIFR Hyderabad laser facility. When the twist of the light matches the handedness of the molecule, the resulting fragment ion yield changes in a measurable way. Reading that change is straightforward: a time-of-flight mass spectrometer sorts the fragments by mass, because lighter ions arrive at the detector sooner, and the team counts how many of each mass appears for the right-handed twist versus the left-handed twist. The contrast between the two fragment distributions is what flags R-camphor against S-camphor.

The team presents a clear OAM-driven fragment-yield contrast for chiral enantiomers in mass spectrometry, a result covered by ScienceDaily's write-up, Nanowerk's coverage, and the IIT Hyderabad science-communication page. For chemists trying to read handedness at speed, the appeal is concrete: the probe is the laser pulse itself, and the readout is a fragment pattern an ordinary mass spectrometer can already produce.

Two caveats qualify that appeal. The demonstration is on camphor, a textbook model compound, at one laser facility, and not on a pharmaceutical candidate in a working analytical lab. And the authors' "faster, simpler, more sensitive" framing is a relative claim against existing chiral-analysis workflows, not a benchmarked result. There is no published head-to-head against polarimetry, chiral chromatography, or photoelectron CD on the same molecule in the same study, and the picture could narrow if such a comparison reverses the result on a different compound, a different pulse length, or a different OAM charge.

Cheaper, faster enantiomer screening matters at the bench before it matters at the bedside. A drug candidate that survives early safety screening as a racemic mixture still has to be re-validated as a single enantiomer before it can ship, and the speed of that handoff affects how many candidates a program can advance in a given year. A method that reads handedness on the same mass spectrometer a lab already owns, with a probe that is a single laser pulse, would shorten the iteration loop from hours to minutes if the contrast holds up beyond camphor.

The mechanism is the news. Structured light has been a working analytical probe in microscopy and trapping for years. Coupling it to mass-spectrometric fragment yields of a chiral molecule, with the contrast turning on light twist, is the new piece. The watch item is the next paper: a benchmark, on a real drug candidate, against the chiral-analysis techniques the pharmaceutical industry already uses.